Alumis Common Stock Stock Today
| ALMS Stock | 8.04 0.33 3.94% |
Performance0 of 100
| Odds Of DistressLess than 49
|
Alumis Common is selling for under 8.04 as of the 24th of December 2024; that is 3.94 percent decrease since the beginning of the trading day. The stock's lowest day price was 8.03. Alumis Common has 49 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. The performance scores are derived for the period starting the 24th of November 2024 and ending today, the 24th of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 28th of June 2024 | Category Healthcare | Classification Health Care |
Alumis Common is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 47.22 M outstanding shares of which 2.43 M shares are presently shorted by private and institutional investors with about 9.71 trading days to cover. More on Alumis Common Stock
Moving together with Alumis Stock
Moving against Alumis Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Alumis Stock Highlights
| CEO President | Martin Babler | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
| Alumis Common can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Alumis Common's financial leverage. It provides some insight into what part of Alumis Common's total assets is financed by creditors. | ||||||||||||||||||||||||||||||||||||||||||||||
Alumis Common Stock (ALMS) is traded on NASDAQ Exchange in USA. It is located in 280 East Grand Avenue, South San Francisco, CA, United States, 94080 and employs 107 people. Alumis Common is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 630.53 M. Alumis Common Stock conducts business under Biotechnology sector and is part of Health Care industry. The entity has 47.22 M outstanding shares of which 2.43 M shares are presently shorted by private and institutional investors with about 9.71 trading days to cover.
Alumis Common generates negative cash flow from operations
Check Alumis Common Probability Of Bankruptcy
Ownership AllocationAlumis Common holds a total of 47.22 Million outstanding shares. The majority of Alumis Common Stock outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Alumis Common Stock to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Alumis Common. Please pay attention to any change in the institutional holdings of Alumis Common Stock as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Alumis Ownership Details
Alumis Common Historical Income Statement
Alumis Stock Against Markets
Alumis Common Corporate Management
| Kolbot By | Senior Operations | Profile | |
| Jorn MD | Chief Development | Profile | |
| Roman MD | Senior Medicine | Profile | |
| Sara Klein | Chief Secretary | Profile | |
| John CFA | Chief Officer | Profile | |
| Kenneth Brameld | Head Fellow | Profile |
Already Invested in Alumis Common Stock?
The danger of trading Alumis Common Stock is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Alumis Common is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Alumis Common. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Alumis Common Stock is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Alumis Stock Analysis
When running Alumis Common's price analysis, check to measure Alumis Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alumis Common is operating at the current time. Most of Alumis Common's value examination focuses on studying past and present price action to predict the probability of Alumis Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alumis Common's price. Additionally, you may evaluate how the addition of Alumis Common to your portfolios can decrease your overall portfolio volatility.